Arcus Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 577
- Market Cap
- -
- Website
- http://www.arcusbio.com
- Introduction
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 610
- Registration Number
- NCT06608927
- Locations
- 🇺🇸
Clinical Research Alliance, New Hyde Park, New York, United States
🇺🇸Summit Cancer Centers - Spokane Valley, Spokane, Washington, United States
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT06120075
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸Sarah Cannon Research Institute, Denver, Colorado, United States
🇺🇸Georgtown, Washington, District of Columbia, United States
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06004921
- Locations
- 🇬🇧
Quotient Sciences - Nottingham, Nottingham, United Kingdom
A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05999513
- Locations
- 🇺🇸
Celerion, Inc., Lincoln, Nebraska, United States
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT05891171
- Locations
- 🇺🇸
Mayo Arizona, Phoenix, Arizona, United States
🇺🇸Mayo Florida, Jacksonville, Florida, United States
🇺🇸Affinity Health Hope and Healing Cancer Services, LLC, Hinsdale, Illinois, United States
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
- Conditions
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 1040
- Registration Number
- NCT05568095
- Locations
- 🇺🇸
UCLA Ronald Reagan Med Ctr, Santa Monica, California, United States
🇺🇸Smillow Cancer Hosp, New Haven, Connecticut, United States
🇺🇸Regions Hospital, Saint Louis Park, Minnesota, United States
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 302
- Registration Number
- NCT05536141
- Locations
- 🇺🇸
Tisch Cancer Institute, Icahn Mount Sinai Hospital, New York, New York, United States
🇦🇺Ashford Cancer Centre Research/ICON, Sydney, Australia
🇺🇸UCLA, Santa Monica, California, United States
A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05411146
- Locations
- 🇳🇱
PRA Health Sciences (PRA) - Early Development Services (EDS), Groningen, NZ, Netherlands
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT05329766
- Locations
- 🇰🇷
Asan Medical Center Hospital, Seoul, Korea, Republic of
🇺🇸Mayo Clinic - Arizona, Phoenix, Arizona, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05277012
- Locations
- 🇺🇸
Investigational Site, Lincoln, Nebraska, United States